Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

Inclusion Criteria: * 18 years of age or older * Chronic HCV genotype 1 infection * Receiving emtricitabine/tenofovir/cobicistat/elvitegravir for at least 8 weeks. * CD4 count \>200 cells/mm3 at screening and no CD4 count \<200 in previous 12 weeks * HIV RNA PCR \<50 copies/ml at screening and no HIV RNA PCR \> 200 copies/ml in previous 12 weeks Exclusion Criteria: * History of integrase inhibitor resistance * History of integrase inhibitor failure * Absolute neutrophil counts under 1500/mm3 ( Black/ African Americans \<1200/mm3 * Patients with cirrhosis * Platelet count under 90,000 per cubic millimeter * Hemoglobin levels \<11 gm/dl in women or \<12 gm/dl in men * Previous treatment with a DAA * Hepatocellular carcinoma * AFP\>100 ng/mL * hepatitis B virus (HBsAg positive) * Evidence of decompensated liver disease including, but not limited to, a history of presence of clinical ascites, bleeding varices, or hepatic encephalopathy